Non-invasive Brain Stimulation System Market By Technology Type (Transcranial Magnetic Stimulation (TMS), Transcranial Direct Current Stimulation (tDCS), Transcranial Alternating Current Stimulation (tACS), Electrocorticography (ECoG)), By Application (Neurological Disorders, Mental Health Treatment), By End-User (Healthcare Providers, Research Institutions, Individuals), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Non-invasive Brain Stimulation System Market was valued at USD 1.9 billion in 2024-e and will surpass USD 3.5 billion by 2030; growing at a CAGR of 10.4% during 2025 - 2030.

The non-invasive brain stimulation (NIBS) systems market is rapidly expanding due to the growing recognition of their therapeutic potential in treating various neurological and mental health conditions. Non-invasive techniques, such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), are becoming increasingly popular due to their ability to modulate brain activity without the need for surgery or invasive procedures. These systems are used to treat a wide range of disorders, from depression to chronic pain, providing a safer and more accessible alternative to traditional treatments.

As the demand for non-invasive therapies grows, advances in technology are enhancing the precision and effectiveness of NIBS systems. The market is poised for further growth as healthcare providers and research institutions explore new applications for these systems, driven by their ability to target specific regions of the brain and provide personalized treatment plans. With the growing focus on mental health and neurological disorders globally, the non-invasive brain stimulation market is set to play a significant role in the future of neurotherapy.

Transcranial Magnetic Stimulation (TMS) is Largest Owing to Effectiveness in Treating Depression

Transcranial magnetic stimulation (TMS) is the largest segment in the non-invasive brain stimulation systems market, owing to its established effectiveness in treating depression and its approval by regulatory bodies like the FDA. TMS uses magnetic fields to stimulate nerve cells in the brain, particularly targeting areas associated with mood regulation. This therapy has been shown to be effective in patients with major depressive disorder (MDD), especially those who have not responded well to traditional antidepressant medications.

TMS has become a widely accepted treatment option for depression, particularly in developed markets, where healthcare systems are increasingly adopting non-invasive treatment methods. Its ability to provide relief without the side effects commonly associated with medications has contributed to its growing popularity. As the clinical evidence supporting the effectiveness of TMS in treating other neurological disorders continues to evolve, its use is expected to expand, solidifying its position as the largest technology in the NIBS market.

Mental Health Treatment Application is Fastest Growing Owing to Increased Focus on Mental Health

Mental health treatment is the fastest growing application in the non-invasive brain stimulation market, driven by the rising global prevalence of mental health disorders such as depression, anxiety, and PTSD. Non-invasive brain stimulation techniques, especially TMS and tDCS, are becoming more commonly used as part of personalized treatment plans for patients who do not respond to conventional therapies. These treatments provide an alternative for patients who are seeking effective options without the side effects associated with traditional psychiatric medications.

The growing awareness and de-stigmatization of mental health issues have resulted in an increased demand for alternative and effective treatments. As NIBS systems gain more recognition for their therapeutic potential in mental health care, they are expected to play an increasingly important role in the management of mental health conditions, contributing to the segment's rapid growth. Furthermore, ongoing research is exploring additional mental health applications, further expanding the market’s potential.

Healthcare Providers End-User Segment is Largest Owing to Increasing Clinical Adoption

Healthcare providers represent the largest end-user segment in the non-invasive brain stimulation market, primarily due to the growing clinical adoption of these systems for treating neurological and mental health disorders. Hospitals, psychiatric clinics, and rehabilitation centers are increasingly incorporating NIBS technologies like TMS and tDCS into their treatment protocols, especially for patients with depression, chronic pain, and cognitive impairments. The ability of these systems to provide targeted treatment with minimal side effects makes them an attractive option for healthcare providers looking for innovative solutions to address complex conditions.

The expansion of healthcare facilities offering non-invasive brain stimulation therapy is contributing to the market's growth. Moreover, insurance coverage for NIBS therapies in certain regions has made them more accessible to a broader patient population. As clinical evidence supporting the efficacy of these treatments continues to build, healthcare providers are expected to increasingly adopt NIBS technologies, solidifying their role as the largest end-user segment in the market.

North America is Largest Region Owing to High Adoption Rates and Advanced Healthcare Infrastructure

North America is the largest region in the non-invasive brain stimulation systems market, owing to its advanced healthcare infrastructure, high adoption rates of innovative therapies, and strong support from regulatory bodies. The United States, in particular, has been a leader in adopting non-invasive brain stimulation technologies, with many healthcare providers offering TMS and tDCS as part of their treatment offerings. The U.S. FDA approval of TMS for the treatment of depression has contributed significantly to the growth of the market in North America.

In addition, the presence of major manufacturers, strong research and development activities, and an increasing focus on mental health have further accelerated market growth in the region. North America’s well-established healthcare system, coupled with a growing interest in non-invasive treatment options, continues to make it the largest market for non-invasive brain stimulation systems. The increasing acceptance of NIBS therapies for treating various conditions is expected to drive further growth in this region.

Competitive Landscape

The non-invasive brain stimulation systems market is highly competitive, with key players including Neuronetics, MagVenture, BrainStimulation, and Fisher Wallace Laboratories. These companies focus on developing and enhancing technologies like TMS and tDCS to cater to the growing demand for effective, non-invasive treatments for mental health and neurological conditions. Companies are also investing in clinical trials and research to expand the indications for their devices, aiming to provide broader therapeutic applications.

Additionally, the market is witnessing increased collaboration between manufacturers and healthcare providers to facilitate the integration of NIBS systems into clinical settings. As the competition intensifies, key players are differentiating themselves by offering products with improved functionality, patient comfort, and greater affordability. With ongoing advancements in technology, the non-invasive brain stimulation market is expected to remain dynamic, with new entrants and innovations continuing to shape the competitive landscape.

Recent Developments:

• In December 2024, MagVenture launched a new version of its TMS system for enhanced treatment of depression and anxiety disorders.
• In November 2024, Fisher Wallace Laboratories announced the release of an updated wearable brain stimulation device for home use.
• In October 2024, NeuroStar expanded its TMS therapy offerings to include Parkinson's disease treatment.
• In September 2024, Nexstim introduced a non-invasive brain stimulation device with improved precision for cognitive enhancement.
• In August 2024, eNeura Therapeutics received regulatory approval for its non-invasive migraine treatment using transcranial magnetic stimulation.

List of Leading Companies:

• MagVenture
• NeuroStar
• Pulsed Therapeutics
• Fisher Wallace Laboratories
• Halo Neuroscience
• Nexstim
• BrainStim
• Soterix Medical
• eNeura Therapeutics
• TMS Neuro Solutions
• Brainnovation
• Transcranial Technologies
• Neuronetics
• Neuroelectrics
• Magstim

Report Scope: